In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials
about
Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studiesArtemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trialMulti-Country Evaluation of Safety of Dihydroartemisinin/Piperaquine Post-Licensure in African Public Hospitals with ElectrocardiogramsRandomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT intervalEffect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria.Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and TanzaniaEvaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria.MMV in partnership: the Eurartesim® experience.Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean womenSafety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis.Piperaquine Population Pharmacokinetics and Cardiac Safety in Cambodia.Use of quantitative pharmacology tools to improve malaria treatments.Natural products modulating the hERG channel: heartaches and hope.Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers.Evidence for the hERG Liability of Antihistamines, Antipsychotics, and Anti-Infective Agents: A Systematic Literature Review From the ARITMO Project.Reduced cardiotoxicity and increased oral efficacy of artemether polymeric nanocapsules in Plasmodium berghei-infected mice.
P2860
Q28535686-7DEC6C2F-B04C-47A9-93A1-001EDB275383Q28542921-E943B5E1-7597-4969-8B88-F1DB4AD25695Q28552793-EBEF673C-1771-4307-A679-C635C4BF7E03Q34298973-967200B3-E270-42C4-8FC5-37BA5BF72606Q34299178-6F203D98-BAB0-42A3-82EE-7C127984D08CQ35519260-1F1DD55C-32AE-49E0-BBB1-6BE4FD8ECAC3Q36125476-FF3F41F4-A3B3-4660-9C04-7F066D9F14B1Q36952896-3B80FE96-C145-421E-A111-0D8D1B713854Q37030663-84292666-21AA-4033-B4D8-A7BD17656B46Q37607325-85C59CEE-F4CA-423D-BBC6-B67B56B1B8ADQ38380902-945AA24B-E100-457E-A1A2-68ED6429803BQ38664529-11C75353-8284-4400-837A-4B65E7CBF16CQ38684705-8F02B88A-C8B3-452D-8D6F-EF87C05B0962Q38684764-1FEB4904-91A4-41F0-9C9C-33AB68728C02Q39055260-3377011F-0794-424D-859C-FFACFF704C7BQ47265841-8F41CA4C-FB6F-46BE-A447-B7791F81456D
P2860
In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
In vitro cardiovascular effect ...... pared with other antimalarials
@ast
In vitro cardiovascular effect ...... pared with other antimalarials
@en
type
label
In vitro cardiovascular effect ...... pared with other antimalarials
@ast
In vitro cardiovascular effect ...... pared with other antimalarials
@en
prefLabel
In vitro cardiovascular effect ...... pared with other antimalarials
@ast
In vitro cardiovascular effect ...... pared with other antimalarials
@en
P2093
P2860
P356
P1476
In vitro cardiovascular effect ...... pared with other antimalarials
@en
P2093
Barb Wible
David Ubben
Franco Borsini
Gan-Xin Yan
Silvia Pace
William Crumb
P2860
P304
P356
10.1128/AAC.05688-11
P407
P577
2012-03-05T00:00:00Z